WFH NETWORK

WFH NETWORK

Overview of the WFH Treatment Guidelines

Glenn Pierce, MD, PhD
WFH Vice President, Medical
The World Federation of Hemophilia has published the third edition of Guidelines for the Management of Hemophilia. Developed through a formal evidence-informed and consensus-based methodology involving multidisciplinary healthcare professionals (HCPs) and well-informed people with hemophilia (PWH), these guidelines offer 340 practical recommendations on managing care for PWH. The guidance provides a framework for the development of a comprehensive healthcare system supporting PWH, including advocacy and patient empowerment.

Browse by chapter

Principles of care

01
Alok Srivastava
MD, FRACP, FRCPA, FRCP
Professor of Medicine Department of Haematology Head, Centre for Stem Cell Research Christian Medical College
Vellore, India

Comprehensive care of hemophilia

02
Kate Khair
PhD
Director of Research, Haemnet, London Centre for Outcomes and Experience Research in Children's Health, Illness and Disability (ORCHID), Great Ormond Street Hospital for Children
London, UK

Genetic assessment

04
Megan Sutherland
PhD
Clinical Scientist Genomic Diagnostics Laboratory Manchester Center for Genomic Medicine Manchester University NHS Foundation Trust Saint Mary's Hospital
Manchester, United Kingdom

Hemostatic agents

05
Steven W. Pipe
MD
Professor of Pediatrics and Pathology Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases Pediatric Director, Hemophilia and Coagulation Disorders Program Director, Special Coagulation Laboratory University of Michigan
Ann Arbor, Michigan, United States

Prophylaxis in hemophilia

06
Manuel Carcao
MD, MSc
Staff Haematologist Co-Director, Hemophilia Clinic Hospital for Sick Children Professor of Paediatrics University of Toronto
Toronto, Ontario, Canada

Treatment of specific hemorrhages

07
Johnny Mahlangu
BSc, MBBCh, MMed, FCPath
Clinical Haematologist, Charlotte Maxeke Johannesburg Academic Hospital and Department of Molecular Medicine and Haematology Professor in Haematology, Faculty of the Health Sciences University of the Witwatersrand and National Health Laboratory Service
Johannesburg, South Africa

Inhibitors to clotting factor

08
Margaret V. Ragni
MD, MPH
Professor of Medicine and Clinical Translational Science Department of Medicine, Division Hematology/Oncology University of Pittsburgh Medical Center Director, Hemophilia Center of Western PA
Pittsburgh, PA

Specific management issues

09
Jerzy Windyga
PhD, MD
Department of Hemostasis Disorders and Internal Medicine IHIT Instytut Hematologii I Transfuzjologii
Warsaw, Poland

Outcome assessment

11
Pradeep M. Poonnoose
MD
Professor, Department of Orthopaedics Christian Medical College
Vellore, India

Methodology

12
Sandra Zelman Lewis
PhD
President, EBQ Consulting, LLC Evidence-based Guidelines and Quality Improvement
Northbrook, Illinois, USA

These materials are derived from the WFH Guidelines for the Management of Hemophilia, 3rd edition [© 2020 World Federation of Hemophilia. Haemophilia © 2020 John Wiley & Sons Ltd]

For the full set of recommendations, please refer to the full WFH Treatment Guidelines, available here.

For questions, contact [email protected]

These educational materials were made possible through the support of the Hemophilia Alliance. 

© World Federation of Hemophilia 2021